---
title: "Mounjaro (tirzepatide), all indications: Safety questions"
description: "Safety questions on Mounjaro (tirzepatide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: Can Mounjaro cause severe stomach problems? Can people with severe gastroparesis take Mounjaro? Does Mounjaro cause thyroid cancer (boxed warning)? Who should not take Mounjaro (contraindications)? 8 further questions follow. 12 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/mounjaro/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide), all indications: Safety questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)  
Indication pages: [Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)

## Warnings

<a id="mounjaro-severe-gi-gastroparesis"></a>

### Can Mounjaro cause severe stomach problems?

> “Use of MOUNJARO has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6)]. In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Use%20of%20MOUNJARO%20has%20been,postmarketing%20with%20GLP%2D1%20receptor%20agonists.)

> “Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Gastrointestinal%3A%20acute%20pancreatitis%2C%20hemorrhagic%20and,severe%20constipation%20including%20fecal%20impaction)

<a id="mounjaro-gastroparesis"></a>

### Can people with severe gastroparesis take Mounjaro?

> “MOUNJARO is not recommended in patients with severe gastroparesis.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=GLP%2D1%20receptor%20agonists.-,MOUNJARO%20is%20not%20recommended%20in%20patients%20with%20severe%20gastroparesis.)

<a id="mounjaro-boxed-warning-thyroid"></a>

### Does Mounjaro cause thyroid cancer (boxed warning)?

> “WARNING: RISK OF THYROID C-CELL TUMORS
> In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
> MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO [see Contraindications (4) and Warnings and Precautions (5.1)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=WARNING%3A%20RISK%20OF%20THYROID%20C%2DCELL,and%20Warnings%20and%20Precautions%20%285.1%29%5D.)

> “Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Routine%20monitoring%20of%20serum%20calcitonin%20or%20using%20thyroid%20ultrasound%20is%20of%20uncertain%20value%20for%20early%20detection%20of%20MTC%20in%20patients%20treated%20with%20MOUNJARO.%20Such%20monitoring%20may%20increase%20the%20risk%20of%20unnecessary%20procedures%2C%20due%20to%20the%20low%20test%20specificity%20for%20serum%20calcitonin%20and%20a%20high%20background%20incidence%20of%20thyroid%20disease.%20Significantly%20elevated%20serum%20calcitonin%20values%20may%20indicate%20MTC%20and%20patients%20with%20MTC%20usually%20have%20calcitonin%20values%20%3E50%20ng%2FL.%20If%20serum%20calcitonin%20is%20measured%20and%20found%20to%20be%20elevated%2C%20the%20patient%20should%20be%20further%20evaluated.%20Patients%20with%20thyroid%20nodules%20noted%20on%20physical%20examination%20or%20neck%20imaging%20should%20also%20be%20further%20evaluated.,-5.2%20Acute%20Pancreatitis)

> “A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5 mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15 mg once weekly based on AUC) administered by subcutaneous injection twice weekly. A statistically significant increase in thyroid C-cell adenomas was observed in males (≥0.5 mg/kg) and females (≥0.15 mg/kg), and a statistically significant increase in thyroid C-cell adenomas and carcinomas combined was observed in males and females at all doses examined. In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10 mg/kg administered by subcutaneous injection twice weekly was not tumorigenic.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=A%202%2Dyear%20carcinogenicity%20study%20was,twice%20weekly%20was%20not%20tumorigenic.)

<a id="mounjaro-contraindications"></a>

### Who should not take Mounjaro (contraindications)?

> “MOUNJARO is contraindicated in patients with:
>
> A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].
> Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO [see Warnings and Precautions (5.4)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%20is%20contraindicated%20in%20patients%20with%3A,%5Bsee%20Warnings%20and%20Precautions%20%285.4%29%5D.)

<a id="mounjaro-pancreatitis"></a>

### Can Mounjaro cause pancreatitis?

> “Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO [see Adverse Reactions (6)].
>
> After initiation of MOUNJARO, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue MOUNJARO and initiate appropriate management.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Acute%20pancreatitis%2C%20including%20fatal%20and,MOUNJARO%20and%20initiate%20appropriate%20management.)

> “In clinical studies, 14 events of acute pancreatitis were confirmed by adjudication in 13 MOUNJARO-treated adult patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure).”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=In%20clinical%20studies%2C%2014%20events,per%20100%20years%20of%20exposure%29.)

> “In the pool of placebo-controlled clinical trials in adults, treatment with MOUNJARO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 33% to 38% and serum lipase concentrations of 31% to 42%. Placebo-treated patients had a mean increase from baseline in pancreatic amylase of 4% and no changes were observed in lipase. The clinical significance of elevations in lipase or amylase with MOUNJARO is unknown in the absence of other signs and symptoms of pancreatitis.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=In%20the%20pool%20of%20placebo%2Dcontrolled%20clinical%20trials%20in%20adults%2C%20treatment,signs%20and%20symptoms%20of%20pancreatitis.)

<a id="mounjaro-gallbladder"></a>

### Can Mounjaro cause gallbladder problems or gallstones?

> “Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.
>
> In MOUNJARO placebo-controlled clinical trials in adults, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Acute%20events%20of%20gallbladder%20disease,appropriate%20clinical%20follow%2Dup%20are%20indicated.)

<a id="mounjaro-kidney"></a>

### Can Mounjaro cause kidney problems?

> “There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, or MOUNJARO. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6)].
>
> Monitor renal function in patients reporting adverse reactions to MOUNJARO that could lead to volume depletion, especially during dosage initiation and escalation of MOUNJARO.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=There%20have%20been%20postmarketing%20reports,initiation%20and%20escalation%20of%20MOUNJARO.)

> “Inform patients of the potential risk of acute kidney injury due to dehydration associated with gastrointestinal adverse reactions. Advise patients to take precautions to avoid fluid depletion. Inform patients of the signs and symptoms of acute kidney injury and instruct them to promptly report any of these signs or symptoms or persistent (or extended) nausea, vomiting, and diarrhea to their healthcare provider [see Warnings and Precautions (5.5)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Inform%20patients%20of%20the%20potential%20risk%20of,%5Bsee%20Warnings%20and%20Precautions%20%285.5%29%5D.)

<a id="mounjaro-diabetic-retinopathy"></a>

### Can Mounjaro worsen diabetic retinopathy?

> “Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Temporary%20worsening%20of%20diabetic%20retinopathy,for%20progression%20of%20diabetic%20retinopathy.)

> “Inform patients to contact their healthcare provider if changes in vision are experienced during treatment with MOUNJARO [see Warnings and Precautions (5.7)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Inform%20patients%20to%20contact%20their,%5Bsee%20Warnings%20and%20Precautions%20%285.7%29%5D.)

<a id="mounjaro-surgery-anesthesia"></a>

### Should Mounjaro be stopped before surgery or anesthesia?

> “MOUNJARO delays gastric emptying [see Clinical Pharmacology (12.2)]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
>
> Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking MOUNJARO, including whether modifying preoperative fasting recommendations or temporarily discontinuing MOUNJARO could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking MOUNJARO.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%20delays%20gastric%20emptying%20%5Bsee,if%20they%20are%20taking%20MOUNJARO.)

## Side effects

<a id="mounjaro-hypersensitivity-injection-site"></a>

### Can Mounjaro cause allergic reactions?

> “Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with MOUNJARO. If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in MOUNJARO [see Contraindications (4), Adverse Reactions (6.2)].
>
> Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with MOUNJARO.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Serious%20hypersensitivity%20reactions%20%28e.g.%2C%20anaphylaxis%2C,to%20these%20reactions%20with%20MOUNJARO.)

> “Hypersensitivity reactions have been reported with MOUNJARO in the pool of placebo-controlled trials in adults, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of MOUNJARO-treated patients compared to 1.7% of placebo-treated patients.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Hypersensitivity%20reactions%20have%20been%20reported,to%201.7%25%20of%20placebo%2Dtreated%20patients.)

<a id="mounjaro-hair-loss"></a>

### Does Mounjaro cause hair loss?

> “The following adverse reactions have been reported during post-approval use of MOUNJARO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20following%20adverse%20reactions%20have,causal%20relationship%20to%20drug%20exposure.)

> “Skin and Subcutaneous Tissue: alopecia”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Skin%20and%20Subcutaneous%20Tissue%3A%20alopecia)

<a id="mounjaro-antibodies"></a>

### Do antibodies to Mounjaro affect how well it works?

> “During the 40- to 104-week treatment periods with ADA sampling conducted up to 44 to 108 weeks in seven clinical trials in adults with type 2 diabetes mellitus [see Clinical Studies (14)], 51% (2,570/5,025) of MOUNJARO-treated patients developed anti-tirzepatide antibodies. In these trials, anti-tirzepatide antibody formation in 34% and 14% of MOUNJARO-treated adult patients showed cross-reactivity to native GIP or native GLP-1, respectively.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=During%20the%2040%2D%20to%20104%2Dweek,GIP%20or%20native%20GLP%2D1%2C%20respectively.)

> “There was no identified clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of MOUNJARO. More MOUNJARO-treated adult and pediatric patients who developed anti-tirzepatide antibodies experienced hypersensitivity reactions or injection site reactions than those who did not develop these antibodies [see Adverse Reactions (6.1)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=There%20was%20no%20identified%20clinically,antibodies%20%5Bsee%20Adverse%20Reactions%20%286.1%29%5D.)

## Related pages
- [Medical information: Mounjaro (tirzepatide): All indications](https://www.evicenter.com/medical-information/mounjaro)
- [Indication](https://www.evicenter.com/medical-information/mounjaro/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/mounjaro/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/mounjaro/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/mounjaro/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/mounjaro/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/mounjaro/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/mounjaro/access-and-coverage)
